`
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________
`
`SAMSUNG BIOEPIS CO., LTD.
`Petitioner,
`
`v.
`
`REGENERON PHARMACEUTICALS, INC.
`Patent Owner.
`
`_______________
`
` IPR2023-008841
`U.S. Patent No. 11,253,572
`
`_______________
`
`PETITIONER’S REQUEST FOR ORAL ARGUMENT
`
`
`
`
`1 IPR2024-00260 and IPR2024-00298 are joined with IPR2023-00884.
`
`
`
`
`
`IPR2023-00884
`
`
`
`Pursuant to 37 C.F.R. § 42.70(a) and the Board’s Second Modified
`
`
`
`
`
`Scheduling Order (Paper 38) entered on March 11, 2024, Petitioner Samsung
`
`Bioepis Co., Ltd. (“Petitioner”) hereby respectfully requests oral argument in this
`
`proceeding. The oral hearing is currently scheduled for August 23, 2024. Paper
`
`38 at 3. Petitioner requests that the Board allot 60 minutes total for the oral
`
`argument, which would be divided equally between the parties (30 minutes per
`
`side). Patent Owner Regeneron Pharmaceuticals, Inc. has indicated it is not in a
`
`position to join this request at this time.
`
`
`
`Petitioner would prefer an in-person hearing, assuming that is convenient for the
`
`Board. Petitioner further requests that in-house counsel and any other non-arguing
`
`attorneys be permitted to attend the oral argument remotely. Petitioner will advise the
`
`Board as to any audio/video request as soon as practicable.
`
`
`
`The issues to be argued include:
`
`1.
`
`The patentability of Claims 1-30 of U.S. Patent No. 11,253,572;
`
`2. Any other issues the Petitioner and Patent Owner properly raised in the
`
`Petition, Patent Owner Response, and Reply in the proceeding;
`
`3. Any other issues that the Board deems necessary for issuing a Final
`
`Written Decision.
`
`
`
`
`
`
`
`2
`
`
`
`IPR2023-00884
`
`DATED: July 8, 2024
`
`
`
`
`
`
`
`
`
`
`
` Respectfully submitted,
`
`
`By /Raymond N. Nimrod/
`Raymond N. Nimrod (Reg. No. 31,987)
`raynimrod@quinnemanuel.com
`Matthew A. Traupman (Reg. No. 50,832)
`matthewtraupman@quinnemanuel.com
`Elliot Choi (admitted pro hac vice)
`elliotchoi@quinnemanuel.com
`QUINN EMANUEL URQUHART
`& SULLIVAN LLP
`51 Madison Avenue, 22nd Floor
`New York, NY 10010
`Tel: (212) 849-7000
`Fax: (212) 849-7100
`
`Zachariah Summers (admitted pro hac vice)
`Sarah Cork (admitted pro hac vice)
`QUINN EMANUEL URQUHART
` & SULLIVAN, LLP
`865 S. Figueroa St., 10th Floor
`Los Angeles, California 90017
`General Tel: (213) 443-3000
`Fax: (213) 443-3100
`zachsummers@quinnemanuel.com
`
`
`Landon Andrew Smith (Reg. No. 79,248)
`landonsmith@quinnemanuel.com
`QUINN EMANUEL URQUHART
` & SULLIVAN, LLP
`300 W. 6th Street
`Austin, TX 78701
`Tel: (737) 667-6100
`Fax: (737) 667-6110
`
`Attorneys for Petitioner Samsung Bioepis
`
`3
`
`
`
`IPR2023-00884
`
`
`
`
`
`
`
`
`
`Certificate of Service (37 C.F.R. § 42.6(e)(4))
`
`I hereby certify that on July 8, 2024, a true and correct copy of the foregoing
`
`Joint Request for Oral Argument was served via electronic mail to counsel for
`
`Petitioner at Regeneron-MoFo-IPR@mofo.com; counsel for Biocon Biologics, Inc. at
`
`MYL_REG_IPR@rmmslegal.com;
`
`and
`
`counsel
`
`for Celltrion,
`
`Inc.
`
`at
`
`lgreen@geminilaw.com,
`
`fchu@geminilaw.com,
`
`rcerwinski@geminilaw.com,
`
`azalcenstein@geminilaw.com, and bmorris@geminilaw.com.
`
`
`
`DATED: July 8, 2024
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`By /Raymond N. Nimrod/
`Raymond N. Nimrod (Reg. No. 31,987)
`raynimrod@quinnemanuel.com
`QUINN EMANUEL URQUHART
` & SULLIVAN, LLP
`51 Madison Ave., 22nd Floor
`New York, NY 10010
`Tel: (212) 849-7000
`Fax: (212) 849-7100
`
`
`4
`
`